FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

NCT02890355 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

123

Enrollment

NIH

Sponsor class

Conditions

Metastatic Pancreatic Adenocarcinoma
Recurrent Pancreatic Carcinoma
Stage IV Pancreatic Cancer AJCC v6 and v7

Interventions

DRUG: Fluorouracil
DRUG: Fluorouracil
DRUG: Irinotecan Hydrochloride
OTHER: Laboratory Biomarker Analysis
DRUG: Leucovorin Calcium
DRUG: Veliparib

Sponsor

National Cancer Institute (NCI)